ERBB2 and breast carcinoma: It is likely that were patients with varying degrees of dependence on FYN or other SFKs, thus focusing on a more optimized clinical patient subgroup may lead to a clearer benefit (e.g. providing trastuzumab in a HER-2 negative breast cancer population versus as HER-2 overexpressing population).